Hemab Therapeutics Holdings, Inc. director Walbert Keli received a stock option award covering 36,000 shares of common stock on September 24, 2026. The exercise price is $35.72 per share, and the resulting option position covers 36,000 underlying shares. The option vests in equal monthly installments over three years, from September 24, 2026 through September 24, 2029, subject to continuous service, and expires September 23, 2036. No Rule 10b5-1 plan is reported.
Hemab Therapeutics Holdings, Inc. (COAG) is identified as the issuer in a Form 3 naming Walbert Keli as a director.
Hemab Therapeutics Holdings, Inc. (COAG) elected Keli Walbert to its Board effective immediately on September 24, 2026. She will serve as a Class I director through the 2027 annual meeting and join the Audit Committee. Under the company’s non-employee director compensation policy, she will receive annual cash compensation of $40,000 for Board service and an additional $10,000 for Audit Committee service, along with annual equity grants and reimbursement of reasonable travel and out-of-pocket expenses for meetings.
She will be granted an option to purchase 36,000 shares at an exercise price equal to the common stock’s closing price on the Grant Date. The option will vest in equal monthly installments through the third anniversary of the Grant Date, subject to continued service, and vesting will accelerate in full upon a change in control.
Novo Holdings A/S, a Danish investment firm wholly owned by Novo Nordisk Foundation, reports a significant position in Hemab Therapeutics Holdings, Inc. common stock. Novo Holdings A/S beneficially owns 4,180,550 shares of Hemab’s common stock, representing 9.0% of the outstanding class.
Novo Holdings A/S has sole voting power and sole dispositive power over all 4,180,550 shares and no shared voting or dispositive power. The filing states that, based on the governance structure of Novo Holdings A/S and Novo Nordisk Foundation, the Foundation is not deemed to have beneficial ownership of these securities.
Hemab’s principal executive offices are located in Cambridge, Massachusetts, while Novo Holdings A/S’s principal business office is in Hellerup, Denmark. The certification section is marked not applicable, and the report is signed by Barbara Fiorini, General Counsel, Finance & Operations of Novo Holdings A/S.
Hemab Therapeutics Holdings, Inc. is the subject of a Schedule 13G reporting that Avoro Capital Advisors LLC, Avoro Ventures LLC and Behzad Aghazadeh collectively report beneficial ownership of 3,298,236 shares of common stock. This represents 7.06% of the common stock, calculated using 46,705,410 shares outstanding as of May 8, 2026, as reported by the company.
Dr. Aghazadeh, as portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures, is listed as a Reporting Person, with sole voting and dispositive power over these shares. The shares were acquired solely for investment purposes on behalf of Avoro Life Sciences Fund LLC and Avoro Ventures Fund L.P., and the Reporting Persons state that the filing should not be construed as an admission of beneficial ownership for Section 13 purposes.
Capital International Investors reported beneficial ownership of Hemab Therapeutics Holdings, Inc. common stock on a Schedule 13G. The firm is deemed to beneficially own 3,603,876 shares, representing 7.7% of Hemab’s common stock, based on 46,705,410 shares believed to be outstanding. Capital International Investors has sole voting and sole dispositive power over all 3,603,876 shares and no shared voting or dispositive power.
Hemab Therapeutics Holdings, Inc. reported as a newly public, clinical-stage biotechnology company focused on blood coagulation disorders. In the quarter ended June 30, 2026, it recorded a net loss of $24.2 million, widening from $12.2 million a year earlier, driven primarily by increased research and development spending on sutacimig, HMB-002 and HMB-003.
For the first six months of 2026, the company’s net loss was $46.8 million. Operating expenses reached $49.7 million, including $39.8 million in research and development and $9.9 million in general and administrative costs, reflecting pipeline expansion and public-company infrastructure.
Hemab completed an IPO on May 4, 2026, issuing 19,262,500 shares at $18.00 per share, generating approximately $317.2 million in net proceeds, and converting 26,496,910 preferred shares into common stock. As of June 30, 2026, it held $457.5 million in cash, cash equivalents and marketable securities and had 46.7 million common shares outstanding. Management states this liquidity is expected to fund operations into 2029. The company discloses existing material weaknesses in internal control over financial reporting and is in the process of remediation.
Hemab Therapeutics Holdings, Inc. reported second quarter 2026 results, highlighting increased investment in its pipeline and a larger loss. For the quarter ended June 30, 2026, operating expenses were $26,079 thousand, up from $16,057 thousand a year earlier, leading to a net loss of $24,150 thousand versus $12,209 thousand in 2025.
The company strengthened its balance sheet in the first half of 2026, with cash and cash equivalents of $237,366 thousand and marketable securities of $220,094 thousand as of June 30, 2026, and total stockholders’ equity of $454,271 thousand. Net cash provided by financing activities was $317,119 thousand in the first six months.
Pipeline progress included FDA endorsement of the sutacimig data package as sufficient to proceed to a Phase 3 pivotal trial in Glanzmann thrombasthenia, with Phase 3 initiation planned in the second half of 2026. New HMB-002 data showed a ≥2.4-fold increase in Von Willebrand Factor and Factor VIII, and Hemab unveiled HMB-003, a novel peptide-based plasmin inhibitor initially targeting heavy menstrual bleeding.
Hemab Therapeutics Holdings, Inc. has been reported as held by a group of related investment entities led by Invus Public Equities and Avicenna Life Sci Master Fund. As of August 5, 2026, Invus Public Equities directly held 2,295,029 shares of common stock and Avicenna Life Sci Master Fund directly held 71,206 shares, for a combined position of 2,366,235 shares. Based on 46,705,410 shares outstanding as of May 8, 2026, the filing shows beneficial ownership percentages of 4.9% for several Invus-related entities and 5.1% for Raymond Debbane, who may be deemed to control multiple reporting entities. The group certifies that the securities are not held for the purpose of changing or influencing control of Hemab Therapeutics Holdings, Inc.
Hemab Therapeutics Holdings Inc has a large institutional shareholder, FMR LLC, which reports beneficial ownership of 3,697,837 shares of the company’s common stock (CUSIP 423494103). This position represents 7.9% of the outstanding common stock as of the reported date.
FMR LLC reports sole voting and sole dispositive power over 3,697,837 shares, with no shared voting or dispositive power. Abigail P. Johnson is reported as having sole dispositive power over the same 3,697,837 shares but no voting power. One or more other persons may have rights to dividends or sale proceeds from these shares, but no such person holds more than five percent of the class.